The TNM staging classification for lung cancer has been updated in the 7th edition, with the most notable changes for thoracic surgeons related to separation of malignant effusion from T4 to M1a, which enables T4N0-1 to be down-staged from stage IIIB to IIIA. In the 1990s, researchers noted that T4N0-1 is a subset of IIIB in the 6th edition of TNM staging classification with better prognosis following surgery, as a retrospective analysis presented by the Southwest Oncology Group 1) suggested that patients with T4N0-1M0 tumors benefited from preoperative chemoradiotherapy and surgery as compared to chemoradiotherapy alone (2-year survival, 64% vs. 33%).
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Most patients with involvement of T4 structures also have mediastinal node involvement. These should be treated with chemoradiotherapy, as that is generally recommended for patients with stage IIIB non-small cell lung cancer (NSCLC). However, a select group of patients with T4 involvement and without mediastinal node involvement can be viewed as candidates for surgery.
2)
The classification of T4 is defined as extending to mediastinum structures. The T4 description has historically been used for locally advanced tumors involving a structure that is considered to be unresectable for curing. Since nonsurgical therapy for T4 tumors is associated with dismal outcome (5-year survival for stage IIIB tumors treated with chemoradiotherapy, 17%-29%), 3) thoracic surgeons have attempted resection of supposedly unresectable structures over the past 3 decades. Lung cancer located on the lateral side occasionally invades the chest wall, and that on the medial side can invade the mediastinum, while the oncological behavior may be the same for tumors in both locations. When T4N0 tumors are entirely resected, the prognosis of the affected patient can be similar to that of those with T3N0 tumors, which are classified as stage IIB. Usually, stage IIB NSCLC is indicated for surgery and commonly performed.
Although a number of reports have demonstrated the technical feasibility of resection of T4 structures, few have provided long-term survival data. The largest studies of resection for T4 involvement involved carinal resections, usually together with a right pneumonectomy, with 12 series of carinal resections for lung cancer reported since 1980. Four of the largest series [4] [5] [6] [7] published since 2000 provided long-term survival data for 395 patients. The 5-year survival rates ranged from 32% to 53% in the N0-1 subset, and 5.3% to 15% in the N2-3 subset. Mortality was from 7.6% to 16% because most cases utilized a sleeve pneumonectomy, and the mortality rate associated with an ordinary pneumonectomy is about 5%, even in Japan. The best 5-year survival rate of 53% came from the largest series and also reported the lowest operative mortality of 7.6%, which suggests that such resections should be undertaken only by experienced surgeons. This may be a reason why T4N0 tumors are not categorized as stage IIB but rather IIIA, in other words, the surgical indication for stage IIIA is only an option for treatment.
A more moderate number of cases (163 patients) had involvement of the superior vena cava (SVC). [8] [9] [10] Those reports include T4 involvement of the SVC as well as nodal involvement. The prognosis for nodal involvement of the SVC is much worse than that for T4 involvement. 9) A pneumonectomy is usually combined with SVC replacement and mortality related to that procedure is reported to range from 7.1% to 12%. No analysis of the T4N0-1 subset was made in those reports. The 5-year survival rate for SVC resection, including N2 disease, is from 21% to 36%, and reports of left atrial involvement in a total of 88 patients have been presented. [11] [12] [13] [14] [15] However, since the number of cases is small, a subset analysis of T4N0-1 tumors separated from T4N2 is not available. The above series reported 3-and 5-year survival rates for patients with T4N0-2 tumors as 39%-54% and 10%-22%, respectively, while smaller studies are available, of tumors invading the spine (45 patients) [16] [17] [18] or aorta (32 patients). 19, 20) Lung cancer with spinal involvement usually occurs in the upper thoracic spine and is most frequently seen as a superior sulcus tumor. Grunenwald 16) reported the outcome of 19 patients following radical en bloc resection for lung cancer invading the spine and noted a 5-year survival rate of 14%, while more recent reports 17, 18) showed a range of 47% to 66.7% for 5-year survival following en bloc vertebrectomy with induction chemoradiotherapy. In a series of patients with aorta invasion, Ohta and colleagues 19) reported 5-year survival rates for T4N0 and T4N2-3 disease of 70% and 16.7%, respectively. Furthermore, Shiraishi and colleagues 20) noted that the outcome of complete resection was much better than that of incomplete resection.
Although surgery for T4N0-1 has become a practical treatment option, it remains technically challenging. The long-term outcome of each organ with T4 involvement should be determined, and the benefits of adding surgery must overcome those of chemoradiotherapy alone. Thoracic surgeons must prepare by adding skills related to broncho-and angio-plastic surgery for the coming new era, and collaborate with cardiovascular and orthopedic surgeons, as well as those from other fields.
